Massachusetts Financial Services Co. MA Sells 4,016 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Massachusetts Financial Services Co. MA decreased its position in Dynavax Technologies Co. (NASDAQ:DVAXFree Report) by 3.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 104,766 shares of the biopharmaceutical company’s stock after selling 4,016 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Dynavax Technologies were worth $1,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BluePath Capital Management LLC acquired a new stake in shares of Dynavax Technologies during the third quarter worth about $33,000. Advisors Asset Management Inc. lifted its stake in Dynavax Technologies by 498.0% during the 1st quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,967 shares during the period. Quantbot Technologies LP increased its stake in shares of Dynavax Technologies by 940.7% in the first quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 2,267 shares during the period. Point72 Middle East FZE purchased a new position in shares of Dynavax Technologies during the fourth quarter worth $53,000. Finally, Metropolitan Life Insurance Co NY lifted its position in Dynavax Technologies by 21.2% during the second quarter. Metropolitan Life Insurance Co NY now owns 7,084 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 1,241 shares during the period. Institutional investors and hedge funds own 99.13% of the company’s stock.

Dynavax Technologies Stock Down 0.8 %

Shares of NASDAQ DVAX opened at $12.82 on Tuesday. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 32.98 and a beta of 1.26. The company’s 50-day simple moving average is $13.69 and its 200-day simple moving average is $13.95. The company has a quick ratio of 14.49, a current ratio of 15.40 and a debt-to-equity ratio of 0.37. Dynavax Technologies Co. has a 52-week low of $9.42 and a 52-week high of $15.15.

Insiders Place Their Bets

In other news, COO David F. Novack sold 20,000 shares of Dynavax Technologies stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.56, for a total value of $271,200.00. Following the sale, the chief operating officer now directly owns 3,187 shares of the company’s stock, valued at $43,215.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO David F. Novack sold 9,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $14.45, for a total value of $130,050.00. Following the completion of the sale, the chief operating officer now owns 3,187 shares of the company’s stock, valued at $46,052.15. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO David F. Novack sold 20,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $13.56, for a total value of $271,200.00. Following the completion of the sale, the chief operating officer now directly owns 3,187 shares of the company’s stock, valued at $43,215.72. The disclosure for this sale can be found here. In the last three months, insiders sold 30,500 shares of company stock worth $423,750. Corporate insiders own 9.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DVAX. JMP Securities boosted their price target on Dynavax Technologies from $25.00 to $27.00 and gave the company a “market outperform” rating in a report on Friday, November 3rd. The Goldman Sachs Group started coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They set a “neutral” rating and a $20.00 price target on the stock. Finally, HC Wainwright lifted their price target on Dynavax Technologies from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 3rd.

Read Our Latest Stock Report on DVAX

About Dynavax Technologies

(Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Read More

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAXFree Report).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.